Coronary/Structural Heart

AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE™ probe in the United States. The cryoSPHERE probe is the first device in the cryoICE family solely dedicated to blocking pain by […]

Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina

VANCOUVER, Feb. 11, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Pierangeli Clinic of Pescara, Italy, under the guidance of its […]

HeartFlow Survey: Fewer than 1/3 of Americans Know Biggest Health Threat

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced the findings of a new consumer survey of more than 1,500 adults across the United States that sheds light on dangerous misconceptions and lack of awareness around heart disease, the leading killer in the U.S. The research shows that while most people are optimistic […]

Confluent Medical Technologies Launches the High-Performance Nitinol Tubing Center of Excellence; Acquires Tube Hollows International (THI) to Now Offer the Most Comprehensive Selection of Nitinol Tubing for High-Performance Implants.

FREMONT, Calif.–(BUSINESS WIRE)–Confluent Medical (formerly Nitinol Devices & Components “NDC”) launched today the High-Performance Nitinol Tubing Center of Excellence in response to increasing market demand for High-Performance Nitinol Tubing in challenging applications such as Transcatheter Heart Valves, Neurovascular, Electrophysiology, and Interventional Pulmonary. Confluent Medical is able to support the Nitinol […]

Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure

PARIS and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of two new scientific articles on the […]

Arterys Named to the 2019 CB Insights AI 100 List

SAN FRANCISCO, Feb. 6, 2019 /PRNewswire/ — Arterys, the leader in intelligent, cloud-based medical image analysis software, today announced that it has been named for the second consecutive year to CB Insights’ coveted AI 100 ranking, which showcases the 100 most promising private artificial intelligence (AI) companies in the world. Arterys was recognized for its […]

Kaneka invests in a US-based medical device company

TOKYO, Feb. 4, 2019 /PRNewswire/ — Kaneka Corporation (Tokyo, Japan, President: Mamoru Kadokura) has entered into an investment and strategic agreement with an undisclosed US-based medical device company (“Company”). According to this agreement, Kaneka has made an investment in 18.5% shares of the Company and plans to start sales as the exclusive distributor […]

American College of Cardiology Acquires MedAxiom

WASHINGTON, Feb. 4, 2019 /PRNewswire/ — The American College of Cardiology Foundation has acquired MedAxiom, a cardiovascular membership, services and consulting firm, adding the company’s recognized leadership in cardiovascular operations, performance improvement, and business acumen to ACC’s world class science, education, registry, quality improvement and advocacy work. Through this acquisition, the ACC will expand […]

CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease

TARRYTOWN, N.Y. and PARIS, Feb. 4, 2019 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Praluent® (alirocumab) Injection, recommending a new indication to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels as an […]

Ascyrus Medical Announces CE Mark Approval for the Ascyrus Medical Dissection Stent (AMDS)

BOCA RATON, FLA. (PRWEB) FEBRUARY 01, 2019 With approval, the AMDS offers physicians and patients in Europe the first marketed arch remodeling device and a breakthrough treatment for type A aortic dissections. Ascyrus Medical, a privately-owned medical device company focused on innovative treatments for aortic dissections, today announced the CE mark […]